2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: Cambridge

Poster-Disease-modifying Therapy

October 25, 2021

Adherence and Persistence to Injectable Disease-Modifying Therapies Among Patients with Multiple Sclerosis Enrolled in US Commercial Plans

Background: In patients with multiple sclerosis (MS), adherence and persistence to disease-modifying therapies (DMTs) are important to...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies

Background: Switching of disease-modifying therapies (DMTs) for treatment of multiple sclerosis (MS) is driven by many factors that are not...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study

Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with...

Read More →

Platform-Disease Modifying Therapies

October 25, 2021

COVID-19 Vaccine Response in People with MS Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy

Background: COVID-19 is a potentially fatal respiratory illness, caused by the novel coronavirus, SARS-CoV-2, which developed into the...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC